Taiwan · Delayed Price · Currency is TWD InnoPharmax Statistics
Total Valuation
InnoPharmax has a market cap or net worth of TWD 1.33 billion. The enterprise value is 1.09 billion.
| Market Cap | 1.33B |
| Enterprise Value | 1.09B |
Important Dates
The next estimated earnings date is Friday, December 4, 2026.
| Earnings Date | Dec 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
InnoPharmax has 119.58 million shares outstanding. The number of shares has increased by 7.80% in one year.
| Current Share Class | 119.58M |
| Shares Outstanding | 119.58M |
| Shares Change (YoY) | +7.80% |
| Shares Change (QoQ) | +7.88% |
| Owned by Insiders (%) | 1.85% |
| Owned by Institutions (%) | 3.64% |
| Float | 44.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 19.76 |
| PB Ratio | 2.52 |
| P/TBV Ratio | 2.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 16.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.42, with a Debt / Equity ratio of 0.02.
| Current Ratio | 6.42 |
| Quick Ratio | 5.95 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.08 |
| Interest Coverage | -563.82 |
Financial Efficiency
Return on equity (ROE) is -37.62% and return on invested capital (ROIC) is -21.64%.
| Return on Equity (ROE) | -37.62% |
| Return on Assets (ROA) | -20.48% |
| Return on Invested Capital (ROIC) | -21.64% |
| Return on Capital Employed (ROCE) | -35.90% |
| Weighted Average Cost of Capital (WACC) | 4.03% |
| Revenue Per Employee | 2.04M |
| Profits Per Employee | -6.17M |
| Employee Count | 33 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 3.07 |
Taxes
In the past 12 months, InnoPharmax has paid 3.51 million in taxes.
| Income Tax | 3.51M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.75% in the last 52 weeks. The beta is -0.04, so InnoPharmax's price volatility has been lower than the market average.
| Beta (5Y) | -0.04 |
| 52-Week Price Change | -42.75% |
| 50-Day Moving Average | 11.45 |
| 200-Day Moving Average | 14.32 |
| Relative Strength Index (RSI) | 48.65 |
| Average Volume (20 Days) | 165,389 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InnoPharmax had revenue of TWD 67.47 million and -203.65 million in losses. Loss per share was -1.82.
| Revenue | 67.47M |
| Gross Profit | 13.22M |
| Operating Income | -192.83M |
| Pretax Income | -200.14M |
| Net Income | -203.65M |
| EBITDA | -191.15M |
| EBIT | -192.83M |
| Loss Per Share | -1.82 |
Balance Sheet
The company has 255.19 million in cash and 11.80 million in debt, with a net cash position of 243.39 million or 2.04 per share.
| Cash & Cash Equivalents | 255.19M |
| Total Debt | 11.80M |
| Net Cash | 243.39M |
| Net Cash Per Share | 2.04 |
| Equity (Book Value) | 529.72M |
| Book Value Per Share | 4.43 |
| Working Capital | 239.39M |
Cash Flow
In the last 12 months, operating cash flow was -150.79 million and capital expenditures -646,000, giving a free cash flow of -151.43 million.
| Operating Cash Flow | -150.79M |
| Capital Expenditures | -646,000 |
| Depreciation & Amortization | 1.68M |
| Net Borrowing | -21.03M |
| Free Cash Flow | -151.43M |
| FCF Per Share | -1.27 |
Margins
| Gross Margin | 19.60% |
| Operating Margin | -285.80% |
| Pretax Margin | -296.64% |
| Profit Margin | n/a |
| EBITDA Margin | -283.32% |
| EBIT Margin | -285.80% |
| FCF Margin | n/a |
Dividends & Yields
InnoPharmax does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.80% |
| Shareholder Yield | -7.80% |
| Earnings Yield | -15.27% |
| FCF Yield | -11.36% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
InnoPharmax has an Altman Z-Score of 18.39 and a Piotroski F-Score of 2.
| Altman Z-Score | 18.39 |
| Piotroski F-Score | 2 |